Dr Casanovas speaks with ecancer at EHA 23 about disease control with BEACOPP in patients with advanced Hodgkin lymphoma.

He discusses the trial design, receiving either 6 cycles of BEACOPP or ABVD chemotherapy depending on PET imaging results, and the consistency in responses between the two trial arms.

The tolerability of BEACOPP treatment-based treatment and higher PFS and OS recommend it as a standard of care.

For more on these results, watch his presentation of the results at a press session.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.